share this article

Some of the 20 most prominent companies, like Atomwise and Pfizer, have announced several new partnerships and new AI-driven processes hinting that AI drug development will witness an explosive growth in the coming years.

The most recent news for Atomwise is the formation of a strategic alliance with Charles River Laboratories International, Inc. The alliance offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest by removing sole reliance on empirical screening. […]

share this article